Novocure files for FDA approval of TTFields for pancreatic cancer
Novocure has filed an application asking the U.S. Food and Drug Administration to approve its Tumor Treating Fields (TTFields) therapy for treating locally advanced…
Pancreatic cancer
KRAS-mutated pancreatic cancer vaccine triggers immune response
A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for preventing disease relapses among people…
Committee recommends study of pancreatic cancer vaccine continue
An independent committee has recommended that a clinical trial testing the experimental anticancer vaccine ELI-002 7P in people with pancreatic cancer should continue as…
Early results ‘extremely positive’ for pancreatic cancer treatment combo
A clinical trial has revealed encouraging results for people with metastatic pancreatic cancer who received Ampligen (rintatolimod) alongside Imfinzi (durvalumab). Nearly two-thirds of…
Verastem’s VS-7375 oral therapy on FDA fast track for pancreatic cancer
The experimental oral medication VS-7375 has been granted fast track designation for advanced pancreatic cancer in the U.S. The Food and Drug Administration (FDA)…
Quemliclustat named orphan drug by FDA for pancreatic cancer
Quemliclustat has been granted an orphan drug designation in the U.S. as a potential treatment for pancreatic cancer. The U.S. Food and Drug Administration…
Daraxonrasib granted breakthrough designation for pancreatic cancer
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with KRAS G12 mutations, has been…
Medicovestor’s pancreatic cancer therapy named FDA orphan drug
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADoBind MC001, an experimental treatment for pancreatic cancer that’s being developed…
Atebimetinib shows potential for advanced pancreatic cancer: Trial
Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment,…
Elraglusib nearly doubles 1-year survival rates in PDAC clinical trial
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
